[Homocystein and cardiovascular risk: is dosage useful?].
Hyperhomocysteinemia represents an independent risk factor for atherothrombotic disease. Physiopathological mechanisms of accelerated progression of atherosclerosis in presence of hyperhomocysteinemia are complex. Herein we report a clinical case which emphasis the importance of screening elevated homocystein in the absence of conventional risk factors in patients who suffer from premature atherosclerosis.
Mathez
Ch
Ch
Service de Médecine B, CHUV, Lausanne.
Trueb
L
L
Darioli
R
R
Waeber
G
G
D000328:Adult; D003324:Coronary Artery Disease / Q000097:blood* / Q000175:diagnosis / Q000235:genetics; D004252:DNA Mutational Analysis; D006580:Genetic Carrier Screening; D006710:Homocysteine / Q000097:blood*; D006801:Humans; D008297:Male; D042965:Methylenetetrahydrofolate Reductase (NADPH2) / Q000235:genetics; D009203:Myocardial Infarction / Q000097:blood* / Q000175:diagnosis / Q000235:genetics; D018455:Protein S Deficiency / Q000097:blood / Q000175:diagnosis / Q000235:genetics; D011516:Prothrombin / Q000235:genetics; D012008:Recurrence; D012307:Risk Factors; D019851:Thrombophilia / Q000097:blood / Q000175:diagnosis / Q000235:genetics
D006710:Homocysteine; D011516:Prothrombin; D042965:Methylenetetrahydrofolate Reductase (NADPH2)